These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. Egbertson MS; Chang CT; Duggan ME; Gould RJ; Halczenko W; Hartman GD; Laswell WL; Lynch JJ; Lynch RJ; Manno PD J Med Chem; 1994 Aug; 37(16):2537-51. PubMed ID: 8057299 [TBL] [Abstract][Full Text] [Related]
9. Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor. Zablocki JA; Miyano M; Rao SN; Panzer-Knodle S; Nicholson N; Feigen L J Med Chem; 1992 Dec; 35(26):4914-7. PubMed ID: 1479591 [No Abstract] [Full Text] [Related]
10. From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus. Blackburn BK; Lee A; Baier M; Kohl B; Olivero AG; Matamoros R; Robarge KD; McDowell RS J Med Chem; 1997 Feb; 40(5):717-29. PubMed ID: 9057858 [TBL] [Abstract][Full Text] [Related]
11. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. Hartman GD; Egbertson MS; Halczenko W; Laswell WL; Duggan ME; Smith RL; Naylor AM; Manno PD; Lynch RJ; Zhang G J Med Chem; 1992 Nov; 35(24):4640-2. PubMed ID: 1469694 [No Abstract] [Full Text] [Related]
12. Inhibition of fibrinogen binding to platelets by MK-852, a new GPIIb/IIIa antagonist. Larsson A; Lindahl TL Ups J Med Sci; 1994; 99(2):121-9. PubMed ID: 7716823 [TBL] [Abstract][Full Text] [Related]
13. The peptides APLHK, EHIPA and GAPL are hydropathically equivalent peptide mimics of a fibrinogen binding domain of glycoprotein IIb/IIIa. Gartner TK; Loudon R; Taylor DB Biochem Biophys Res Commun; 1991 Nov; 180(3):1446-52. PubMed ID: 1953789 [TBL] [Abstract][Full Text] [Related]
14. Structural and functional aspects of RGD-containing protein antagonists of glycoprotein IIb-IIIa. Lazarus RA; McDowell RS Curr Opin Biotechnol; 1993 Aug; 4(4):438-45. PubMed ID: 7763974 [TBL] [Abstract][Full Text] [Related]
15. Development of 1,4-benzodiazepine cholecystokinin type B antagonists. Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510 [TBL] [Abstract][Full Text] [Related]
16. Mambin, a potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor structurally related to the short neurotoxins. McDowell RS; Dennis MS; Louie A; Shuster M; Mulkerrin MG; Lazarus RA Biochemistry; 1992 May; 31(20):4766-72. PubMed ID: 1591238 [TBL] [Abstract][Full Text] [Related]
17. Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists. Kerwin JF; Nadzan AM; Kopecka H; Lin CW; Miller T; Witte D; Burt S J Med Chem; 1989 Apr; 32(4):739-42. PubMed ID: 2704023 [No Abstract] [Full Text] [Related]
18. Low molecular weight, non-peptide fibrinogen receptor antagonists. Alig L; Edenhofer A; Hadváry P; Hürzeler M; Knopp D; Müller M; Steiner B; Trzeciak A; Weller T J Med Chem; 1992 Nov; 35(23):4393-407. PubMed ID: 1447740 [TBL] [Abstract][Full Text] [Related]